Want to see LRMR full AI Analyst Report?
LRMR Stock Chart & Stats
$4.17
-$0.11(-2.75%)
At close: 4:00 PM EDT
$4.17
-$0.11(-2.75%)
Day’s Range― - ―
52-Week Range$1.92 - $6.42
Previous CloseN/A
Volume458.18K
Average Volume (3M)1.55M
Market Cap
$220.23M
Enterprise Value$167.06M
Total Cash (Recent Filing)$156.27M
Total Debt (Recent Filing)$4.96M
Price to Earnings (P/E)―
Beta1.94
Next Earnings
Nov 05, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.99
Shares Outstanding103,882,935
10 Day Avg. Volume1,814,713
30 Day Avg. Volume1,552,368
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)3.56
Price to Sales (P/S)0.00
P/FCF Ratio-2.45
Enterprise Value/Market Cap0.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.97
Forecast
1Y Price Target
$16.33Price Target Upside291.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.37
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory PathwayFDA alignment on frataxin as a novel surrogate endpoint and acceptance of a rolling BLA create a defined regulatory path for nomlabofusp. Completing the package as planned could shorten the route from development to potential accelerated approval and commercialization.
Clinical ProgressLonger-term data showing generally manageable safety across more than 10,000 doses and sustained frataxin increases strengthen the lead program’s clinical foundation. Directional improvements in outcome measures also support continued development and potential differentiation in Friedreich’s ataxia.
Funding RunwayCash, cash equivalents and marketable securities of $156.3 million, with runway projected into the third quarter of 2027, provide funding visibility through planned Phase 3 work. This supports execution of regulatory and launch preparations before near-term financing becomes necessary.
Bears Say
No Commercial RevenueZero revenue across multiple reporting periods confirms that Larimar remains dependent on clinical development rather than an established commercial product. Until nomlabofusp is approved and launched, the business lacks recurring operating revenue to offset research, regulatory and launch expenditures.
Widening LossesLosses have expanded materially as Larimar advances its lead program and prepares for potential commercialization, raising the scale of ongoing funding requirements. Persistent negative earnings reduce financial self-sufficiency and leave results highly dependent on clinical and regulatory execution.
Accelerating Cash BurnAccelerating operating cash outflows indicate that development and commercial-readiness spending is consuming capital at a rising rate. Even with current liquidity, deeply negative free cash flow means future financing or other capital sources may remain important as Phase 3 and launch activities progress.
Larimar Therapeutics News
LRMR FAQ
What was Larimar Therapeutics, Inc.’s price range in the past 12 months?
Larimar Therapeutics, Inc. lowest stock price was $1.92 and its highest was $6.42 in the past 12 months.
What is Larimar Therapeutics, Inc.’s market cap?
Larimar Therapeutics, Inc.’s market cap is $220.23M.
When is Larimar Therapeutics, Inc.’s upcoming earnings report date?
Larimar Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 16 days.
How were Larimar Therapeutics, Inc.’s earnings last quarter?
Larimar Therapeutics, Inc. released its earnings results on Aug 04, 2026. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.381 by $0.081.
Is Larimar Therapeutics, Inc. overvalued?
According to Wall Street analysts Larimar Therapeutics, Inc.’s price is currently Undervalued.
Does Larimar Therapeutics, Inc. pay dividends?
Larimar Therapeutics, Inc. does not currently pay dividends.
What is Larimar Therapeutics, Inc.’s EPS estimate?
Larimar Therapeutics, Inc.’s EPS estimate is -0.34.
How many shares outstanding does Larimar Therapeutics, Inc. have?
Larimar Therapeutics, Inc. has 103,882,935 shares outstanding.
What happened to Larimar Therapeutics, Inc.’s price movement after its last earnings report?
Larimar Therapeutics, Inc. reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.381. Following the earnings report the stock price went up 3.266%.
Which hedge fund is a major shareholder of Larimar Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LRMR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Larimar Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.33 (291.69% Upside)
$16.33 (291.69% Upside)
Blogger Sentiment
Bullish
LRMR Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 162.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.52%
12-Months-Change
Fundamentals
Return on Equity
-137.39%
Trailing 12-Months
Asset Growth
10.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Larimar Therapeutics, Inc.
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
LRMR Stock 12 Month Forecast
Average Price Target
$16.33
▲(291.69% Upside)
Technical Analysis
Omeros
―
Vanda
―
Foghorn Therapeutics
―
Candel Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
36.03% Insiders
5.48% Mutual Funds
0.56% Other Institutional Investors
49.14% Public Companies and
Individual Investors